OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--SpyBiotech, a biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, today announced a sponsored research agreement with The University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).

英国牛津和马萨诸塞州剑桥。-（商业新闻短讯）--SpyBiotech是一家拥有新型疫苗平台技术的生物技术公司，可针对传染病，癌症和慢性病，今天宣布与牛津大学签署赞助研究协议，以开发针对爱泼斯坦-巴尔病毒（EBV）的疫苗。

EBV is a commonly spread virus that can lead to several serious health conditions including infectious mononucleosis and is linked to various cancers and multiple sclerosis. This research project will combine Oxford’s groundbreaking academic research capabilities with SpyBiotech’s proprietary SPYVLP platform technology in order to advance three vaccine candidates targeting EBV and test these in a Phase I clinical trial..

EBV是一种常见的传播病毒，可导致多种严重的健康状况，包括传染性单核细胞增多症，并与各种癌症和多发性硬化症有关。该研究项目将牛津大学开创性的学术研究能力与SpyBiotech专有的SPYVLP平台技术相结合，以推进三种针对EBV的候选疫苗，并在I期临床试验中进行测试。。

“This research collaboration is an important step forward on a commonly spread virus with no currently available vaccines or therapeutics for its prevention or spread,” said Mark Leuchtenberger, Chief Executive Officer of SpyBiotech. “Studies have found that EBV triggers a range of very serious health conditions including certain cancers and multiple sclerosis.

SpyBiotech首席执行官Mark Leuchtenberger说：“这项研究合作是针对一种普遍传播的病毒迈出的重要一步，目前尚无预防或传播的疫苗或疗法。”。“研究发现，EBV会引发一系列非常严重的健康状况，包括某些癌症和多发性硬化症。

A recent study led by Stanford Medicine and senior author Dr. William Robinsoni notes that 99% of MS patients have EBV antibodies in their blood, indicating prior infection. We see a great need for a vaccine against EBV.”.

斯坦福医学院（Stanford Medicine）和资深作者威廉·罗宾逊（William Robinsoni）博士最近领导的一项研究指出，99%的MS患者血液中含有EBV抗体，表明先前感染过。我们认为非常需要一种针对EBV的疫苗。”。

SpyBiotech’s novel SPYVLP vaccine platform is based on a proprietary protein “superglue” technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. Under the terms of this agreement, SpyBiotech will provide Oxford researchers with access to the SPYVLP vaccine platform, and the Oxford team will work to advance the research into a Phase 1 clinical trial to be conducted through the University..

SpyBiotech的新型SPYVLP疫苗平台基于专有的蛋白质“超级胶”技术，该技术将抗原与疫苗递送平台结合，从而最大程度地降低递送风险并增强免疫原性和功效。根据该协议的条款，SpyBiotech将为牛津大学的研究人员提供SPYVLP疫苗平台的访问权限，牛津大学的团队将致力于将该研究推进到将通过该大学进行的第一阶段临床试验。。

“We are very keen to progress these vaccine candidates that target multiple EBV antigens to Phase I clinical trials with Professor Sandy Douglas and his team at the Jenner Institute, University of Oxford after seeing the promising pre-clinical data generated,” said Sumi Biswas, Ph.D., President and CSO of SpyBiotech..

SpyBiotech总裁兼CSO Sumi Biswas博士说：“我们非常渴望与牛津大学詹纳研究所的Sandy Douglas教授及其团队合作，将这些针对多种EBV抗原的候选疫苗推进I期临床试验，因为他们看到了有希望的临床前数据。”。。

The company is currently conducting a Phase I trial assessing safety and immunogenicity of its HCMV vaccine. The study features a six-month dosing schedule and is being carried out in the UK.

该公司目前正在进行一期试验，评估其HCMV疫苗的安全性和免疫原性。这项研究的特点是为期六个月的给药时间表，目前正在英国进行。

About Epstein-Barr virus (EBV)

关于爱泼斯坦-巴尔病毒（EBV）

EBV is transmitted through saliva and is one of the most commonly spread human virusesii. Most people recover within a few weeks, but for some individuals EBV can lead to a number of health conditions including mononucleosis, meningitis, encephalitis and certain cancersiii. Recent research suggests people with multiple sclerosis and some lymphomas are more likely to have been infected with the virus.

EBV通过唾液传播，是最常见的人类病毒之一。大多数人在几周内康复，但对于某些人来说，EBV可能导致多种健康状况，包括单核细胞增多症、脑膜炎、脑炎和某些癌症。最近的研究表明，患有多发性硬化症和某些淋巴瘤的人更有可能感染该病毒。

There are no currently available vaccines or therapeutics for the prevention or treatment of EBV..

目前尚无用于预防或治疗EBV的疫苗或疗法。。

About SpyBiotech

关于SpyBiotech

SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and chronic diseases. The company was spun out of the University of Oxford in 2017 by Oxford Science Enterprises (OSE) and Google Ventures (GV). The company raised $32.5 million in a Series A equity financing in 2021.

SpyBiotech是一家临床阶段生物技术公司，拥有针对传染病、癌症和慢性病的新型疫苗平台技术。该公司于2017年由牛津科学企业（OSE）和谷歌风险投资（GV）从牛津大学分拆出来。2021年，该公司在a系列股权融资中筹集了3250万美元。

Based on science developed at the University of Oxford, SpyBiotech’s novel vaccine platform is based on a proprietary protein “superglue” technology which binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer.

基于牛津大学开发的科学，SpyBiotech的新型疫苗平台基于专有的蛋白质“超级胶”技术，该技术将抗原与疫苗递送平台结合，以最大程度地降低递送风险并增强免疫原性和功效。这使得它非常适合在发展中国家等具有挑战性的环境中用于防治传染病，但也可能在癌症等非传染病环境中应用。

SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag/SpyCatcher and related “superglue” technologies in vaccine development. www.spybiotech.com.

SpyBiotech拥有牛津大学的专有权，可以在疫苗开发中应用、商业化和再许可SpyTag/SpyCatcher和相关的“超级胶”技术。www.spybiotech.com。

i Stanford Medicine. (2022, January 24). Study identifies how Epstein-Barr virus triggers multiple sclerosis. https://med.stanford.edu/news/all-news/2022/01/epstein-barr-virus-multiple-sclerosis.html

我是斯坦福医学院的。（2022年1月24日）。这项研究确定了爱泼斯坦-巴尔病毒如何引发多发性硬化症。https://med.stanford.edu/news/all-news/2022/01/epstein-barr-virus-multiple-sclerosis.html

ii Centers for Disease Control and Prevention. (2020, September 28). About Epstein-Barr virus (EBV). Centers for Disease Control and Prevention. https://www.cdc.gov/epstein-barr/about/?CDC_AAref_Val=https://www.cdc.gov/epstein-barr/about-ebv.html

疾病控制和预防中心。（2020年9月28日）。关于爱泼斯坦-巴尔病毒（EBV）。疾病控制和预防中心。https://www.cdc.gov/epstein-barr/about/?CDC_AAref_Val=https://www.cdc.gov/epstein-barr/about-ebv.html

iii Centers for Disease Control and Prevention. (2020b, September 28). Epstein-Barr and mononucleosis: For Healthcare Providers. Centers for Disease Control and Prevention. https://www.cdc.gov/epstein-barr/hcp.html

疾病控制和预防中心。（2020b年9月28日）。爱泼斯坦·巴尔和单核细胞增多症：针对医疗保健提供者。疾病控制和预防中心。https://www.cdc.gov/epstein-barr/hcp.html